Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pfizer to Market Generics of Over 20 APIs in 2011
January 24, 2011
- classA Network Considers Introducing Point Service Program
January 24, 2011
- Small Generic Makers to Increasingly Specialize in Development, Manufacturing: JGA President Sawai
January 24, 2011
- JACDS to Call on Members to Temporarily Refrain from Offering Points for Dispensing Services
January 24, 2011
- Mr Hosokawa Reappointed Health Minister
January 24, 2011
- LSIP Signs 1st Agreements for Patents on Apoptosis, Stem Cells
January 24, 2011
- Pfizer Applies for Prevnar 13 in Adult Patients in US, Europe
January 24, 2011
- Takeda Licenses Biomarker for Alzheimer's Disease from Zinfandel
January 24, 2011
- Prospects for Simultaneous Global Development: 4
January 24, 2011
- Ono Enters Target Discovery Agreement with BioFocus for Autoimmune Disease
January 24, 2011
- Minodronate vs Raloxifene to Be Compared in IIT
January 24, 2011
- Astellas Expands Marketing Territory for Eligard
January 24, 2011
- Office of Medical Innovation to Begin Full Operation
January 24, 2011
- Daiichi Sankyo Transfers Marketing of Kremezin in Japan to MTPC
January 24, 2011
- BI, Eli Lilly Tie Up to Develop Antidiabetic Agents
January 24, 2011
- GSK Licenses Parkinson's Disease Drug from Impax
January 24, 2011
- AZ Enters 2nd Decade of Leap in 2011: President Kato
January 24, 2011
- Teijin Pharma to Market Kenketsu Venilon, Anact C in Kyushu
January 24, 2011
- HSB's Cancer-Related Budget Up ¥2.7 Bil. to ¥34.3 Bil. in FY2011
January 17, 2011
- Korosho Requires Thorough Explanations on OTC Cold Medicines before Sale
January 17, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…